WO2008013807A3 - A novel lactic acid formulation of mk-0457 useful for the treatment of cancer - Google Patents
A novel lactic acid formulation of mk-0457 useful for the treatment of cancer Download PDFInfo
- Publication number
- WO2008013807A3 WO2008013807A3 PCT/US2007/016637 US2007016637W WO2008013807A3 WO 2008013807 A3 WO2008013807 A3 WO 2008013807A3 US 2007016637 W US2007016637 W US 2007016637W WO 2008013807 A3 WO2008013807 A3 WO 2008013807A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- useful
- treatment
- lactic acid
- acid formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07796994A EP2051737A2 (en) | 2006-07-26 | 2007-07-24 | A novel lactic acid formulation of mk-0457 useful for the treatment of cancer |
AU2007277226A AU2007277226A1 (en) | 2006-07-26 | 2007-07-24 | A novel lactic acid formulation of MK-0457 useful for the treatment of cancer |
JP2009521803A JP2009544705A (en) | 2006-07-26 | 2007-07-24 | MK-0457 novel lactic acid formulation useful for cancer treatment |
CA002658436A CA2658436A1 (en) | 2006-07-26 | 2007-07-24 | A novel lactic acid formulation of mk-0457 useful for the treatment of cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83344206P | 2006-07-26 | 2006-07-26 | |
US60/833,442 | 2006-07-26 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2008013807A2 WO2008013807A2 (en) | 2008-01-31 |
WO2008013807A3 true WO2008013807A3 (en) | 2008-04-03 |
WO2008013807A9 WO2008013807A9 (en) | 2009-03-12 |
Family
ID=38863098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/016637 WO2008013807A2 (en) | 2006-07-26 | 2007-07-24 | A novel lactic acid formulation of mk-0457 useful for the treatment of cancer |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2051737A2 (en) |
JP (1) | JP2009544705A (en) |
CN (1) | CN101500613A (en) |
AU (1) | AU2007277226A1 (en) |
CA (1) | CA2658436A1 (en) |
WO (1) | WO2008013807A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2982890C (en) * | 2015-04-17 | 2023-08-22 | Ludwig Institute For Cancer Research Ltd | Plk4 inhibitors |
WO2017146253A1 (en) | 2016-02-26 | 2017-08-31 | 公益財団法人がん研究会 | Screening method of anticancer agent focused on function of hp1, and evaluation system |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007014250A2 (en) * | 2005-07-26 | 2007-02-01 | Vertex Pharmaceuticals Incorporated | Abl kinase inhibition |
WO2007136615A2 (en) * | 2006-05-16 | 2007-11-29 | Merck & Co., Inc. | Combination cancer therapy |
-
2007
- 2007-07-24 WO PCT/US2007/016637 patent/WO2008013807A2/en active Application Filing
- 2007-07-24 CN CNA2007800287245A patent/CN101500613A/en active Pending
- 2007-07-24 EP EP07796994A patent/EP2051737A2/en not_active Withdrawn
- 2007-07-24 AU AU2007277226A patent/AU2007277226A1/en not_active Abandoned
- 2007-07-24 CA CA002658436A patent/CA2658436A1/en not_active Abandoned
- 2007-07-24 JP JP2009521803A patent/JP2009544705A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007014250A2 (en) * | 2005-07-26 | 2007-02-01 | Vertex Pharmaceuticals Incorporated | Abl kinase inhibition |
WO2007136615A2 (en) * | 2006-05-16 | 2007-11-29 | Merck & Co., Inc. | Combination cancer therapy |
Non-Patent Citations (3)
Title |
---|
DOGGRELL SHEILA A: "Dawn of Aurora kinase inhibitors as anticancer drugs.", EXPERT OPINION ON INVESTIGATIONAL DRUGS SEP 2004, vol. 13, no. 9, September 2004 (2004-09-01), pages 1199 - 1201, XP002467064, ISSN: 1744-7658 * |
HARRINGTON E A ET AL: "VX-680, A Potent and Selective Small-Molecule Inhibitor of the Aurora Kinases, Suppress Tumor Growth In Vivo", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 10, no. 3, March 2004 (2004-03-01), pages 262 - 267, XP003014821, ISSN: 1078-8956 * |
WANG Y ET AL: "VX-680/MK-0457. Aurora kinase inhibitor oncolytic", DRUGS OF THE FUTURE 2007 SPAIN, vol. 32, no. 2, 2007, pages 144 - 147, XP002467063, ISSN: 0377-8282 * |
Also Published As
Publication number | Publication date |
---|---|
WO2008013807A2 (en) | 2008-01-31 |
WO2008013807A9 (en) | 2009-03-12 |
AU2007277226A1 (en) | 2008-01-31 |
CN101500613A (en) | 2009-08-05 |
EP2051737A2 (en) | 2009-04-29 |
CA2658436A1 (en) | 2008-01-31 |
JP2009544705A (en) | 2009-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2273975B8 (en) | Pharmaceutical solutions, process of preparation and therapeutic uses | |
TN2012000428A1 (en) | Bisaryl-bonded aryltriazolones and use thereof | |
MX2010006033A (en) | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof. | |
WO2008104306A3 (en) | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof | |
WO2009105774A3 (en) | Amino acid inhibitors of cytochrome p450 | |
WO2007106537A3 (en) | Aminoquinolones as gsk-3 inhibitors | |
UA92861C2 (en) | Pharmaceutical composition for treating depression and process for the preparation thereof | |
TW200724532A (en) | Pyrimidinecarboxylic acid derivatives and their use | |
WO2008119457A3 (en) | Lactam-substituted dicarboxylic acids and use thereof | |
WO2007018588A8 (en) | Stable pharmaceutical composition comprising linezolid form iv | |
WO2007105015A3 (en) | DERIVATIVES OF 18ß-GLYCYRRHETINIC ACID | |
WO2008136394A1 (en) | Method for production of lactam compound, and intermediate for the production method | |
WO2010088450A3 (en) | Arylamide derivatives useful in the treatment of diseases associated with serca activity | |
WO2008022345A3 (en) | Compositions and methods for inhibiting cytochrome p450 | |
UA102238C2 (en) | 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof | |
WO2008052139A3 (en) | Ultra low dose doxepin and methods of using the same to treat sleep disorders | |
EP2019133A4 (en) | MICROORGANISM CAPABLE OF PRODUCING gamma-L-PGA, METHOD FOR PRODUCTION OF gamma-L-PGA USING THE MICROORGANISM, CROSSLINKED PRODUCT, AND AGENT FOR EXTERNAL APPLICATION TO THE SKIN | |
WO2009099553A3 (en) | Use of kinase inhibitor in treatment of atherosclerosis | |
WO2010090494A3 (en) | Medical use of 5-benzylaminosalicylic acid derivatives or salts thereof | |
WO2010121675A3 (en) | Thiazolyl-benzimidazoles | |
TW200745132A (en) | Novel, acyclically substituted furopyrimidine derivatives and use thereof | |
WO2008019782A3 (en) | Dispersions of nanoureas containing active ingredients | |
WO2011076208A3 (en) | Calcipotriol monohydrate nanocrystals | |
WO2011009532A3 (en) | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzylidene derivatives, methods for the production thereof and use thereof for treating diseases | |
WO2007140804A8 (en) | A process for the preparation of an oxaliplatin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780028724.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07796994 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2658436 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 428/DELNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009521803 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007277226 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007277226 Country of ref document: AU Date of ref document: 20070724 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007796994 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |